Posts

Electra Targets Nearly $300M IPO

on

Allarity Therapeutics Files Registration Statement for Proposed $100 Million SPAC IPO

on

AbbVie-backed ADARx files for IPO to fund clinical-stage siRNA pipeline

on

Electra Therapeutics files for Nasdaq IPO to fund Phase 2/3 immunology program

on

Biotech IPOs Near a Breakthrough—But Valuation and Preclinical Risks Remain

on

Braveheart lands ~$383M IPO to take Hengrui cardio drug into Phase 3

on

Attovia CEO Fu plans muscle in on itch market with $289M IPO to challenge Dupixent

on

Latigo targets $272M+ IPO to fund rival Nav1.8 pain drug to Vertex’s Journavx

on

Apnimed secures $192M upsized IPO to launch sleep apnea pill Oxnimbi

on

Caldera snaps up Synlogic in reverse merger to hit Nasdaq and fund IBD pipeline through 2029

on

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

on

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

There is always a first: Why US biotech Axiom will begin its IPO journey in Hong Kong

on

I&I startup Attovia files to go public as biotech listings momentum builds

on

Post-Hoc Live: What's making biotech IPOs work again?

on

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on

Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

on

UPDATED: Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on